This document provides information on disease modifying therapies (DMTs) licensed for use in the UK to treat multiple sclerosis (MS). It outlines the 7 DMT drugs approved, including beta interferons, glatiramer acetate, natalizumab, and fingolimod. It describes how these drugs work to reduce inflammation and immune cell activity that causes MS symptoms. Side effects, dosage regimens, storage requirements, and reasons for stopping or switching drugs are discussed. Travel tips and additional resources for patients prescribed DMTs are also mentioned.